skip to main content
US FlagAn official website of the United States government
dot gov icon
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
https lock icon
Secure .gov websites use HTTPS
A lock ( lock ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Explore Research Products in the PAR
It may take a few hours for recently added research products to appear in PAR search results.


Title: An overview of the effect of bioaerosol size in coronavirus disease 2019 transmission
Abstract The fast spread of coronavirus disease 2019 (COVID‐19) constitutes a worldwide challenge to the public health, educational and trade systems, affecting the overall well‐being of human societies. The high transmission and mortality rates of this virus, and the unavailability of a vaccine or treatment, resulted in the decision of multiple governments to enact measures of social distancing. Such measures can reduce the exposure to bioaerosols, which can result in pathogen deposition in the respiratory tract of the host causing disease and an immunological response. Thus, it is important to consider the validity of the proposal for keeping a distance of at least 2 m from other persons to avoid the spread of COVID‐19. This work reviews the effect of aerodynamic diameter (size) of particles carrying RNA copies of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). A SARS‐CoV‐2 carrier person talking, sneezing or coughing at distance of 2 m can still provide a pathogenic bioaerosol load with submicron particles that remain viable in air for up to 3 h for exposure of healthy persons near and far from the source in a stagnant environment. The deposited bioaerosol creates contaminated surfaces, which if touched can act as a path to introduce the pathogen by mouth, nose or eyes and cause disease.  more » « less
Award ID(s):
1903744
PAR ID:
10383844
Author(s) / Creator(s):
 
Publisher / Repository:
Wiley Blackwell (John Wiley & Sons)
Date Published:
Journal Name:
The International Journal of Health Planning and Management
Volume:
36
Issue:
2
ISSN:
0749-6753
Page Range / eLocation ID:
p. 257-266
Format(s):
Medium: X
Sponsoring Org:
National Science Foundation
More Like this
  1. ; ; ; ; ; ; ; ; ; ; et al (, Biosensors and Bioelectronics: X)
    Rapid and accurate detection of the pathogens, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for COVID-19, is critical for mitigating the COVID-19 pandemic. Current state-of-the-art pathogen tests for COVID-19 diagnosis are done in a liquid medium and take 10–30 min for rapid antigen tests and hours to days for polymerase chain reaction (PCR) tests. Herein we report novel accurate pathogen sensors, a new test method, and machine-learning algorithms for a breathalyzer platform for fast detection of SARS-CoV-2 virion particles in the aerosol in 30 s. The pathogen sensors are based on a functionalized molecularly-imprinted polymer, with the template molecules being the receptor binding domain spike proteins for different variants of SARS-CoV-2. Sensors are tested in the air and exposed for 10 s to the aerosols of various types of pathogens, including wild-type, D614G, alpha, delta, and omicron variant SARS-CoV-2, BSA (Bovine serum albumin), Middle East respiratory syndrome–related coronavirus (MERS-CoV), influenza, and wastewater samples from local sewage. Our low-cost, fast-responsive pathogen sensors yield accuracy above 99% with a limit-of-detection (LOD) better than 1 copy/μL for detecting the SARS-CoV-2 virus from the aerosol. The machine-learning algorithm supporting these sensors can accurately detect the pathogens, thereby enabling a new and unique breathalyzer platform for rapid COVID-19 tests with unprecedented speeds. 
    more » « less
  2. ; ; ; ; ; ; ; ; ; (, Science)
    null (Ed.)
    The future trajectory of the coronavirus disease 2019 (COVID-19) pandemic hinges on the dynamics of adaptive immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, salient features of the immune response elicited by natural infection or vaccination are still uncertain. We use simple epidemiological models to explore estimates for the magnitude and timing of future COVID-19 cases, given different assumptions regarding the protective efficacy and duration of the adaptive immune response to SARS-CoV-2, as well as its interaction with vaccines and nonpharmaceutical interventions. We find that variations in the immune response to primary SARS-CoV-2 infections and a potential vaccine can lead to markedly different immune landscapes and burdens of critically severe cases, ranging from sustained epidemics to near elimination. Our findings illustrate likely complexities in future COVID-19 dynamics and highlight the importance of immunological characterization beyond the measurement of active infections for adequately projecting the immune landscape generated by SARS-CoV-2 infections. 
    more » « less
  3. (, Annual Review of Ecology, Evolution, and Systematics)
    The coronavirus disease 2019 (COVID-19) pandemic challenged the workings of human society, but in doing so, it advanced our understanding of the ecology and evolution of infectious diseases. Fluctuating transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) demonstrated the highly dynamic nature of human social behavior, often without government intervention. Evolution of SARS-CoV-2 in the first two years following spillover resulted primarily in increased transmissibility, while in the third year, the globally dominant virus variants had all evolved substantial immune evasion. The combination of viral evolution and the buildup of host immunity through vaccination and infection greatly decreased the realized virulence of SARS-CoV-2 due to the age dependence of disease severity. The COVID-19 pandemic was exacerbated by presymptomatic, asymptomatic, and highly heterogeneous transmission, as well as highly variable disease severity and the broad host range of SARS-CoV-2. Insights and tools developed during the COVID-19 pandemic could provide a stronger scientific basis for preventing, mitigating, and controlling future pandemics. 
    more » « less
  4. ; ; ; ; ; ; ; ; ; ; et al (, Frontiers in Immunology)
    Background Limited data are available regarding the balance of risks and benefits from human milk and/or breastfeeding during and following maternal infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Objective To investigate whether SARS-CoV-2 can be detected in milk and on the breast after maternal coronavirus disease 2019 (COVID-19) diagnosis; and characterize concentrations of milk immunoglobulin (Ig) A specific to the SARS-CoV-2 spike glycoprotein receptor binding domain (RBD) during the 2 months after onset of symptoms or positive diagnostic test. Methods Using a longitudinal study design, we collected milk and breast skin swabs one to seven times from 64 lactating women with COVID-19 over a 2-month period, beginning as early as the week of diagnosis. Milk and breast swabs were analyzed for SARS-CoV-2 RNA, and milk was tested for anti-RBD IgA. Results SARS-CoV-2 was not detected in any milk sample or on 71% of breast swabs. Twenty-seven out of 29 (93%) breast swabs collected after breast washing tested negative for SARS-CoV-2. Detection of SARS-CoV-2 on the breast was associated with maternal coughing and other household COVID-19. Most (75%; 95% CI, 70-79%; n=316) milk samples contained anti-RBD IgA, and concentrations increased ( P =.02) during the first two weeks following onset of COVID-19 symptoms or positive test. Milk-borne anti-RBD IgA persisted for at least two months in 77% of women. Conclusion Milk produced by women with COVID-19 does not contain SARS-CoV-2 and is likely a lasting source of passive immunity via anti-RBD IgA. These results support recommendations encouraging lactating women to continue breastfeeding during and after COVID-19 illness. 
    more » « less
  5. ; ; ; ; (, Royal Society of Chemistry)
    At the end of 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel human coronavirus, emerged and rapidly caused a global pandemic. SARS-CoV-2 is the causative agent of coronavirus disease 2019 (COVID-19), which affects the respiratory tract and lungs of infected individuals. Due to the increased transmissibility of the SARS-CoV-2 virus compared to its previous versions, determining as fully as possible the various structural aspects of the virus became critical for the development of therapeutics and vaccines to combat this virus. Knowing the structures of viral proteins and their glycosylation is an essential foundation for the understanding of the mechanism of the disease. Glycopeptide analysis has been used to map the glycosylation of viral glycoproteins, including those of influenza and HIV. Thanks to the developments in the field over the last few decades, scientists were able to quickly develop therapeutics against SARS-CoV-2. This chapter discusses the four structural proteins of SARS-CoV-2, their glycosylation and modifications, and the techniques used to map SARS-CoV-2 glycosylation. 
    more » « less
  • Citation Formats
  • MLA
  • APA
  • Chicago
  • BibTeX
  • Save / Share this Record
  • Send to Email